Swedish Orphan Biovitrum
318,8
SEK
-1,24 %
SOBI
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
5 investorer følger denne virksomhed
-1,24%
+0,44%
+4,39%
+4,32%
+16,95%
+18,25%
+80,31%
+112,11%
+568,08%
Swedish Orphan Biovitrum, also known as Sobi, is an international pharmaceutical company. The company is focused on the research and development of treatments and belonging services for patients with rare diseases. The products are mainly focused on the treatment of inflammatory and genetic diseases. Sobi also markets specialized wound patches under various brands. The head office is located in Stockholm.
Læs mereMarkedsværdi
113,49 mia. SEK
Aktieomsætning
33,03 mio. SEK
Omsætning
22,12 mia.
EBIT %
18,38 %
P/E
42,68
Udbytteafkast, %
-
Finanskalender
5.2
2025
Årsrapport '24
29.4
2025
Delårsrapport Q1'25
8.5
2025
Generalforsamling '24
ViserAlle indholdstyper
Notice of Extraordinary General Meeting in Swedish Orphan Biovitrum AB (publ)
Swedish Orphan Biovitrum AB: David Meek is proposed as new Chair of the Board of Directors of Sobi
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools